Plain-English translation of NCT05156060 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether and , taken together three times a day, can help prevent and treat pain in people with locally advanced head and neck cancer who are undergoing radiation or chemotherapy treatment. Researchers want to find the right dose of the medication that works safely and is tolerable for patients, while also measuring how well it helps with pain, symptoms, daily functioning, and quality of life.
Many people with head and neck cancer experience severe acute and chronic pain during and after their cancer treatment. This trial exists to see whether this medication combination could offer a better way to manage that pain and improve patients' comfort and quality of life during a difficult treatment course.
You likely qualify if…
You likely don't qualify if…
As a participant, you would take and together three times per day throughout your cancer treatment and beyond. The study team will monitor you closely to check how well you tolerate the medication and track your pain levels, symptoms, and quality of life through visits and assessments. The researchers will start at a lower dose and gradually increase it to find the safest and most effective dose for you.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Natalie Lockney
Enrollment target
~64 participants
Started
January 2022
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
21 Years and older
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Vanderbilt-Ingram Service for Timely Access
Vanderbilt-Ingram Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.